Glycemicon Company
Glycemicon AG is a Swiss biotechnology company developing novel nutraceuticals for managing prediabetes, diabetes and obesity, using new approaches that were initially developed at the University of Science & Technology ETH Zurich. The lead product’s active substance is a naturally-occurring bile acid, THBA, which drives changes to the body fat architecture that combat elevated blood glucose levels.
Glycemicon stands for "glycemic control" - the maintenance of healthy blood sugar levels, which is the aim of every individual living with prediabetes and diabetes.
Headquarters:
Brügg, Bern, Switzerland, Europe
Founded Date:
2013-01-01
Industry:
Longevity Supplements & Protocols
Employee Number:
11-50
Super Industry:
Longevity
Phone Number:
+41 56 560 50 20
Investors:
Venture Kick
Ipo Status:
private
City:
Brügg
Region:
Bern
Country:
Switzerland
Founders:
Christian Wolfrum, Erick M Carreira, Nadja Mrosek, Peter Harboe Schmidt, Richard Cribiù